Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    temsirolimus AND GIST | Open Studies
Show Display Options
Download search resultsDownload the search results for:
temsirolimus AND GIST | Open Studies (2 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
Conditions: Carcinoma, Renal Cell, Advanced;   Lymphoma, Mantle-Cell;   Gastrointestinal Stroma Tumors
Interventions: Drug: Temsirolimus;   Drug: Sunitinib;   Drug: Axitinib
2 Recruiting Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Conditions: Solid Tumors;   Triple-Negative Breast Cancer;   Non Small Cell Lung Cancer;   Renal Cell Carcinoma;   Mesothelioma;   Fumarate Hydratase (FH)-Deficient Tumors;   Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST);   Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors;   Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations;   Tumors Harboring Amplifications in the cMyc Gene
Interventions: Drug: CB-839;   Drug: Pac-CB;   Drug: CBE;   Drug: CB-Erl;   Drug: CBD;   Drug: CB-Cabo

Study has passed its completion date and status has not been verified in more than two years.